1.50469
Purospher® STAR RP-18 endcapped (3 µm)
L × I.D. 100 mm x 4.6 mm Hibar® RT HPLC column
Synonym(s):
Purospher® STAR RP-18 endcapped (3µm) Hibar® RT 100-4.6
About This Item
Recommended Products
material
stainless steel column
Quality Level
Agency
suitable for USP L1
product line
Purospher®
feature
endcapped
packaging
1 ea of
extent of labeling
17% Carbon loading
parameter
400 bar pressure
65 °C max. temp.
technique(s)
HPLC: suitable
LC/MS: suitable
mass spectrometry (MS): suitable (High)
column L × I.D.
10 cm × 4.6 mm
surface area
330 m2/g
matrix
fully porous particle
matrix active group
C18 bonding phase
particle size
3 μm
pore size
120 Å pore size
operating pH range
1.5-10.5
separation technique
reversed phase
supercritical fluid (SFC)
storage temp.
no temp limit
Related Categories
General description
Application
Features and Benefits
- Ultra-pure silica (99.999%) for excellent peak symmetry
- High separation efficiency
- Reproducible results from run-to-run and batch-to-batch
- Best all-round performance according to Tanaka
- Outstanding pH stability from pH 1.5 to 10.5
- No phase collapse when using highly aqueous mobile phases
- Good suitability for LC-MS applications
Analysis Note
Theoretical Plates (N/m) (Anthracene): ≥ 120000
Symmetry (Anthracene): 0.8 - 1.4
Capacity factor (Anthracene): 4.0 - 6.0
Legal Information
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Protocols
Aripiprazole is an atypical antipsychotic and a partial dopamine agonist. It is primarily used in the treatment of schizophrenia, bipolar disorder, major depressive disorder, tic disorders, and irritability associated with autism. Aripiprazole was first approved by the U.S. Food and DrugAdministration in November 2002 for schizophrenia and by the European Medicines Agency in June 2004 for acute manic and mixed episodes associated with bipolar disorder.
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service